Sparc to manufacture graphene additive coatings

Graphene technology company Sparc Technologies has developed a commercial manufacturing process for the production of graphene based additive products, and will begin manufacture. The company has identified, trailed and ordered specialised graphene based additive manufacturing equipment and has located a manufacturing site. Sparc managing director Mike Bartels said: “Our path to commercialisation is now clear…

Details

Siemens technology underpins critical research on Australia’s reef systems

Advertising feature The Great Barrier reef is a spectacular ecological landscape, and home to thousands of unique marine species, from deep water corals to whales, sharks and sea turtles. The roughly 344,400 square kilometre tropical ecosystem is the largest living structure on the planet, and consists of 3,000 individual reefs, each with their own complex…

Details

$200bn on offer through food value-adding

An additional 300,000 jobs could be created within Australia’s food and agribusiness sector by 2030 through industry value-adding, according to a re[port for industry growth centre Food Innovation Australia Ltd (FIAL). FIAL and consultant AlphaBeta Singapore found that if opportunities are realised this could unlock $200 billion in value across each state and territory. They…

Details

Affinity windows revamps its glass house

Australian manufacturers change hands every day, but for Affinity Windows, part of BCG Australia WA, preparing for sale sparked a root and branch modernisation of operations. Peter Roberts reports. Affinity Windows is well known in Western Australia, supplying residential and commercial customers with aluminium windows, doors, security products, shower screens and robes. Fairly standard products…

Details

Trials begin of Australian-developed Covid-19 vaccine

A second Australian-developed and manufactured Covid-19 vaccine has surfaced with the University of Adelaide commencing human trials of its new vaccine that targets the highly-transmissible Omicron variant of the disease. Manufactured by Adelaide company BioCina, the university’s DNA-based vaccine is being trialled at Royal Adelaide Hospital in partnership with PARC Clinical Services and SA Pathology.…

Details